Read more

March 11, 2020
1 min read
Save

Microdose therapies for myopia, presbyopia being studied

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ATLANTA – Eyenovia is evaluating atropine for progressive myopia and pilocarpine for presbyopia in several studies using the company’s Optejet microdose dispenser.

April Jasper, OD, medical monitor for Eyenovia’s studies, told Primary Care Optometry News here at SECO that 36-month data from the CHAPERONE study of the MicroPine formulation for treating progressive myopia is expected in 2023, and phase 3 trials for VISION 1 and 2, which are evaluating episodic treatment of presbyopia, will be completed this year.

Jasper explained that the capacity of the eye is 8 mL of fluid, and most eye drops comprise 40 mL. Eyenovia’s microdose dispenser delivers 75% less solution in a mist. It maintains efficacy; causes fewer side effects, including hyperemia; and results in fewer systemic effects, she said.

The all-in-one drug and dispenser mists the eye in 80 milliseconds, Jasper said, while the blink reflex is 100 milliseconds, so the solution, “gets into the eye faster than you can blink.”

The dispenser also contains Bluetooth technology to track patients’ use. – by Nancy Hemphill, ELS, FAAO

Disclosure: Jasper reports she is a medical monitor for Eyenovia.